Brokerages Set Natera, Inc. (NASDAQ:NTRA) Price Target at $178.12

Shares of Natera, Inc. (NASDAQ:NTRA - Get Free Report) have earned an average rating of "Buy" from the sixteen analysts that are presently covering the stock, MarketBeat reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $178.12.

NTRA has been the topic of several recent analyst reports. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Piper Sandler upped their price target on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th.

Natera Stock Up 0.7 %

NTRA traded up $1.03 during trading on Friday, reaching $149.25. The company had a trading volume of 1,325,380 shares, compared to its average volume of 1,342,578. The business's fifty day moving average price is $163.70 and its 200 day moving average price is $148.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market cap of $20.18 billion, a P/E ratio of -84.80 and a beta of 1.80.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Equities analysts anticipate that Natera will post -1.49 EPS for the current year.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the sale, the director now directly owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. The trade was a 29.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 298,946 shares of company stock valued at $47,803,462. Company insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Natera

Several large investors have recently bought and sold shares of the company. Assetmark Inc. boosted its position in Natera by 2.1% during the 3rd quarter. Assetmark Inc. now owns 7,353 shares of the medical research company's stock worth $933,000 after buying an additional 150 shares during the period. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after purchasing an additional 95 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of Natera during the third quarter worth $270,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Natera by 29.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 671,382 shares of the medical research company's stock worth $85,232,000 after purchasing an additional 153,441 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Natera by 4.2% in the third quarter. Victory Capital Management Inc. now owns 315,543 shares of the medical research company's stock valued at $40,058,000 after purchasing an additional 12,815 shares during the period. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.